<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538924</url>
  </required_header>
  <id_info>
    <org_study_id>2MI-1</org_study_id>
    <nct_id>NCT04538924</nct_id>
  </id_info>
  <brief_title>Etiologic Mechanisms, Myocardial Changes and Prognosis of Patients With MINOCA</brief_title>
  <official_title>Multimodality Study on Etiologic Mechanisms, Myocardial Changes, and Prognosis of Patients With Myocardial Infarction With Non-obstructive Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University Hospital Santaros Klinikos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Council of Lithuania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vilnius University Hospital Santaros Klinikos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective trial will include 150 patients with myocardial infarction with&#xD;
      non-obstructive coronary arteries (MINOCA). A thorough clinical, laboratory and imaging&#xD;
      evaluation will be performed by novel biomarkers and modern imaging techniques (heart&#xD;
      magnetic resonance imaging and noninvasive testing). Moreover, two different treatment groups&#xD;
      will be distinguished. Additionally, a retrospective analysis of patients meeting MINOCA&#xD;
      criteria will be performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary goals The primary trial goal is to assess the etiologic mechanisms of myocardial&#xD;
      damage in patients with MINOCA as well as to evaluate a variety of therapeutic strategies for&#xD;
      these patients.&#xD;
&#xD;
      Secondary goals&#xD;
&#xD;
        1. To assess functional and morphological myocardial changes in patients with MINOCA;&#xD;
&#xD;
        2. To assess the true prevalence and prognostic relevance of MINOCA (all-cause mortality&#xD;
           and MACE);&#xD;
&#xD;
        3. To test the effect of conventional acute MI therapies (BB, ACEI, ARB, CCB, statins,&#xD;
           anti-platelet agents) on MACE (death and myocardial infarction) and all-cause mortality&#xD;
           in patients with MINOCA;&#xD;
&#xD;
        4. To test the diagnostic and prognostic role of several biomarkers (sST2, BNP, cTnI, CRP,&#xD;
           copeptin, procalcitonin, MR-proADM, galectin-3) in patients with MINOCA;&#xD;
&#xD;
        5. To assess the impact of MINOCA with respect to chronic health status, such as persistent&#xD;
           angina symptoms, impairment in quality of life, and depression;&#xD;
&#xD;
        6. To evaluate systemic microcirculation status and assess its effect on long term&#xD;
           outcomes.&#xD;
&#xD;
        7. To evaluate hospital mortality and all-cause death within 6 and 12 months follow-up;&#xD;
&#xD;
        8. To determine recurrent hospitalizations within 30-days, 6 and 12 months follow-up;&#xD;
&#xD;
        9. To assess peak creatine kinase, creatine kinase-MB and troponin levels during hospital&#xD;
           stay;&#xD;
&#xD;
       10. To determine quality of life at 6 and 12 months assessed using the Euroqol 5D (EQ-5D)&#xD;
           questionnaire (www.euroqol.org).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of all-cause mortality</measure>
    <time_frame>12 months follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of cardiovascular death</measure>
    <time_frame>12 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalization for MI</measure>
    <time_frame>12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MACE</measure>
    <time_frame>12 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myocardial Infarction With Nonobstructive Coronary Arteries</condition>
  <arm_group>
    <arm_group_label>MINOCA (group I) - conventional MI treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Traditional MI treatment with optimal doses of statin, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB), beta-blockers (BB) and dual antiplatelet therapy (DAPT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MINOCA (group II)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with a low-dose statin and ACEI/ARB. In case of vasospasm, calcium channel blockers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>extended clinical, laboratory and instrumental examination; treatment options comparison</intervention_name>
    <description>Multimodality investigation and different treatment comparison</description>
    <arm_group_label>MINOCA (group I) - conventional MI treatment</arm_group_label>
    <arm_group_label>MINOCA (group II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. acute MI:&#xD;
&#xD;
               -  detection of a rise and/or fall of cardiac troponin(cTn) values with at least one&#xD;
                  value above the 99th percentile upper reference limit (URL) and with at least one&#xD;
                  of the following:&#xD;
&#xD;
               -  symptoms of acute myocardial ischaemia;&#xD;
&#xD;
               -  new ischaemic ECG changes;&#xD;
&#xD;
               -  development of pathological Q waves;&#xD;
&#xD;
               -  imaging evidence of new loss of viable myocardium or new regional wall motion&#xD;
                  abnormality in a pattern consistent with an ischaemic aetiology&#xD;
&#xD;
          2. non-obstructive coronary arteries on angiography:&#xD;
&#xD;
             - the absence of obstructive coronary artery disease (CAD) on angiography, (i.e. no&#xD;
             coronary artery stenosis ≥50%), in any potential infarct-related artery;&#xD;
&#xD;
             This includes both patients with:&#xD;
&#xD;
               -  normal or near normal coronary arteries (no stenosis &gt;30%)&#xD;
&#xD;
               -  mild coronary atheromatosis (stenosis &gt;30% but &lt;50%).&#xD;
&#xD;
          3. angiography performed within 24 - 48 hours&#xD;
&#xD;
          4. age &gt;18 years&#xD;
&#xD;
          5. informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute kidney failure&#xD;
&#xD;
          -  stage 4-5 chronic kidney disease&#xD;
&#xD;
          -  contraindications for coronary angiography or CMR&#xD;
&#xD;
          -  patients involved in another biomedical trial&#xD;
&#xD;
          -  inability to make a decision to participate in the investigation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rokas Šerpytis</last_name>
    <phone>+37061089860</phone>
    <email>rserpytis@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rokas Šerpytis</last_name>
      <phone>+37061089860</phone>
      <email>rserpytis@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University Hospital Santaros Klinikos</investigator_affiliation>
    <investigator_full_name>Rokas Šerpytis</investigator_full_name>
    <investigator_title>Principal Investigator; MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

